• Hematology and Oncology
    • Director of the Drug Development Unit, and Head of the Prostate Cancer Targeted Therapy Group at The Institute of Cancer Research
    Professor Johann de Bono is a Professor in Experimental Cancer Medicine at The Institute of Cancer Research and Royal Marsden. He is the Director of The Drug Development Unit, overseeing the conduct of Phase I trials, with a particular interest in innovative trial designs, circulating biomarkers and prostate cancer. He also leads the Prostate Cancer Targeted Therapy Clinical Trials Team and the Cancer Biomarkers laboratory team. He graduated from the University of Glasgow medical school in 1989, graduating as a Member of the Royal College of Physicians (MRCP) in 1992. He was awarded a four-year Cancer Research Campaign Clinical Fellowship, which allowed him to pursue a PhD between 1993 and 1997. He trained in medical oncology, and was awarded an MSc (Cancer Sciences) from Glasgow University. The Royal College of Physicians and Surgeons of Glasgow then awarded him a travelling scholarship that allowed him to pursue further research on the challenges of clinical trial design at the SWOG statistical headquarters at the Fred Hutchinson Cancer Centre in Seattle, USA in 1999. Between 2000 and 2003 he then pursued further research developing novel anti-cancer drugs at the Institute for Drug Development within the University of Texas Health Science Centre at San Antonio. In 2003, he was elected a Fellow of the Royal College of Physicians, and in 2009, he was elected as a Member of the Malta Order of Merit. Professor de Bono received the prestigious ESMO Award in 2012 and was part of the ICR/RMH team awarded the AACR Team Science Award. He also received an award from the Royal Society of Chemistry for his team’s work in developing abiraterone. Professor de Bono has been involved in the development of many novel agents, many of which are now approved drugs, functioning as chief investigator on Phase I trials such as abiraterone, olaparib and afatinib. He has served as chief investigator of multiple drugs that have changed the standard of care for prostate cancer patients including abiraterone, cabazitaxel and enzalutamide and has published more than 300 manuscripts including multiple publications in the New England Journal of Medicine and The Lancet. He has led on the study of circulating tumour cells, whole blood expression profiling and plasma DNA in metastatic prostate cancer patients and pioneered the concept of patient molecular stratification in early clinical trials in the Pharmacological Audit Trail.
    • Deputy Director (Research), Clinical Trials and Statistics Unit at The Institute of Cancer Research
    Emma Hall PhD CStat is Deputy Director of the Cancer Research UK funded Clinical Trials and Statistics Unit at the Institute of Cancer Research (ICR-CTSU). The ICR-CTSU is UK Clinical Research Collaborative registered and is one of fifteen CTUs recognised by the UK National Cancer Research Institute for a professional specialism in the development and delivery of cancer trials. Within the context of ICR’s strategy of developing precision medicine, ICR-CTSU aims to initiate, conduct and analyse clinical trials that will be at the forefront of changes to clinical practice within the National Health Service and overseas. ICR-CTSU’s main interests and areas of expertise are phase II/III randomised trials that evaluate new drug treatments and technologies (including radiotherapy) and/or utilise biomarker-driven designs to clinically qualify putative predictive biomarkers. Dr Hall leads ICR-CTSU’s portfolio in urological and head and neck cancers. Dr Hall is a medical statistician with interests in both cancer clinical trials and epidemiology having gained an MSc in Statistics with Applications in Medicine (University of Southampton, 1994) and a PhD in Epidemiology (University College London, 1999). She is a Chartered Statistician and fellow of the Royal Statistical Society and has membership of the Society for Clinical Trials and the International Society of Clinical Biostatistics. Dr Hall is a member of the National Clinical Research Institute (NCRI)’s Prostate and Bladder Clinical Studies Groups and its Clinical and Translational Radiotherapy Research Group Executive Committee. She sits on a number of independent data monitoring and trial steering committees for international/national phase II and III trials.
    • Clinical Pathology
    The research in my lab is focused on functional genomic, proteomic and bioinformatics approaches to study cancer for the purposes of understanding cancer biology as well as to discover clinical biomarkers. My group has characterized a number of important biomarkers of prostate cancer including AMACR, EZH2, the sarcosine metabolite, and most recently the long non-coding RNA (lncRNA) Schlap1. AMACR is being used clinically across the country in the assessment of cancer in prostate needle biopsies. Our landmark study thus far is the discovery of TMPRSS2-ETS gene fusions in prostate cancer. TMPRSS2-ETS gene fusions are specific markers of prostate cancer as well as presumably function as rational targets for this disease. This finding potentially redefines the molecular basis of prostate cancer as well as other common epithelial cancers. Staining for the most common gene fusion product, TMPRSS2-ERG, is available in pathology laboratories for molecular subtyping of prostate cancer and the assessment of clinically challenging foci assessed by prostate needle biopsy. In mid-2013, detection of TMPRSS2-ERG combined with the lncRNA PCA3 in urine will be available in CLIA reference laboratories for the detection of clinically significant prostate cancer (licensed and developed with Gen-Probe/Hologic). Currently we are looking for ways to target this gene fusion as well as discover similar gene fusions in other common epithelial tumors such as those derived from the breast, lung, and colon. A clinical trial is underway (with the University of Michigan as the lead site) attempting to target the gene fusions in prostate cancer. I also led the development of the popular cancer profiling bioinformatics resource called Oncomine ( (hosting over 20,000 registered users from over 30 countries and serving 16 of the 20 top oncology biopharma). Most recently, I have been involved in developing high-throughput clinical sequencing approaches for precision oncology (i.e., MI-ONCOSEQ). This has led to a number of discoveries including the pathognomomic gene fusion for solitary fibrous tumor (SFT) as well as diverse targetable gene fusions of FGFR across a diverse array of common solid tumors. We also identified activating mutations in ESR1 that are a key mechanism in acquired endocrine resistance in breast cancer therapy.
    • Medical Oncology
    Team Leader at the Vall Hebron Institute of Oncology
    Team Leader at the Vall Hebron Institute of Oncology

    Joaquin Mateo is a physician-scientist and medical oncologist. He leads the Prostate Cancer Translational Research lab at Vall Hebron Institute of Oncology in Barcelona. After completing medical school and clinical training in Medical Oncology, he joined the The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research (London) in 2011, where he pursued his PhD in Prof. Johann de Bono´s laboratory, developing first-in-man clinical trials of several PARP inhibitors and compounds targeting the PI3K-AKT-mTOR pathway, with particular interest in developing novel therapies for prostate cancer patients in parallel to developing predictive biomarkers for a more genomics-tailored patient care. His main interest is the integration of tumor molecular characterisation data into real-time clinical decision-making for patients through multidisciplinary tumor boards.

    • Scientist at The Institute of Cancer Research
    Suzanne Carreira, PhD received her BSc in Biochemistry and PhD in Molecular Biology from the Faculty of Sciences at the University of Aix-Marseille III in the south of France. Dr Carreira then pursued a postdoctoral fellowship at the Marie Curie Research Institute in Oxted UK, to investigate the signal transduction pathways and transcriptional regulation that operate in the melanocyte lineage and to understand the progression to malignancy. She then joined the Virology Division at Imperial College London as a Research Associate to investigate the physiological role and regulation of the liver specific factor CREB-H, member of a new family of ER anchored transcription factors involved in ER stress response. Dr Suzanne Carreira joined The Institute of Cancer Research Cancer Biomarkers Group of Prof. de Bono in 2011 where she developed Next Generation Sequencing of patient tumour tissue samples and circulating free DNA for patient molecular characterisation and the delivery of personalised medicine.
Powered by Medstro